Samuel D. Isaly is a founder and the Managing Partner of OrbiMed Advisors. Mr. Isaly is one of the world's most recognized healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Mr. Isaly has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, SoGen Swiss International, Gramercy Associates and S.G. Warburg. Mr. Isaly launched OrbiMed's asset management business in 1989. Mr. Isaly has a B.A. in Economics from Princeton University and a M. Sc. (Econ.) from The London School of Economics.

Back to Top

Sven H. Borho, CFA, is a founding General Partner of OrbiMed. Mr. Borho is a portfolio manager for OrbiMed's public equity funds and he heads the firm's trading efforts. He started his career in 1991 when he joined Mehta and Isaly as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Mr. Borho became portfolio manager to investment funds under management. Mr. Borho studied business administration at Bayreuth University in Germany and received a M. Sc. (Econ.) from The London School of Economics; he is a citizen of both Germany and Sweden.

Back to Top

Geoffrey C. Hsu, CFA, is a General Partner of OrbiMed. He joined OrbiMed in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Mr. Hsu received his A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Prior to business school, he spent two years studying medicine at Harvard Medical School.

Back to Top

Richard D. Klemm, Ph.D., CFA, is a Public Equity Partner focused on biotechnology companies. He completed a Ph.D. from the Massachusetts Institute of Technology in molecular biology in 2000. Dr. Klemm has published scientific articles in the fields of DNA replication and transcription. He received a B.A. from the University of California, Berkeley in 1994 with majors in molecular and cell biology and economics.

Back to Top

Trevor M. Polischuk, Ph.D., is a Public Equity Partner focused on the global pharmaceutical industry. Previously, he worked at Lehman Brothers as a Senior Research Analyst covering the U.S. pharmaceutical industry. Dr. Polischuk began his career at Warner Lambert as a member of the Pharmaceutical Global Marketing Planning team. In this role, he coordinated marketing activities for the second generation gabapentinoid product, Pregabalin. Dr. Polischuk holds a Doctorate in Neuropharmacology & Gross Human Anatomy from Queen's University and an MBA from Queen's University.

Back to Top

C. Scotland Stevens is a Public Equity Partner focused on equity derivatives and trading strategies. Mr. Stevens was previously a Vice President at Goldman, Sachs & Co., responsible for stock and derivatives trading for healthcare hedge fund investors globally. He received an M.B.A. in Finance and Healthcare from The Wharton School at the University of Pennsylvania. Prior to business school, Mr. Stevens worked for the Investment Banking Group at Wachovia Securities and for Pfizer. He has a B.S. in Business Administration and Chemistry from the University of North Carolina at Chapel Hill.

Back to Top

William F. Sawyer is a Public Equity Partner focused on generic and specialty pharmaceutical companies. Prior to joining OrbiMed, he worked at Leerink Swann and Company as a senior analyst covering the specialty pharmaceutical sector. Prior to his tenure at Leerink Swann, he worked as an associate on the specialty pharmaceutical research teams of Merrill Lynch and Lehman Brothers. Mr. Sawyer received his B.S. Pharmacy degree from Rutgers University and his M.B.A. from New York University.

Back to Top

Andrew P. Kanarek, CFA, joined OrbiMed in 1998 to focus on equity trading and operations. Previously, he was a research associate at Mehta and Isaly. Mr. Kanarek completed a B.S. in Chemistry from New York University and a B.E. in Chemical Engineering from Stevens Institute of Technology.

Back to Top

Jason A. Kahn joined OrbiMed in 1999 as an Equity Trader. Mr. Kahn was previously a research associate at National Securities Corporation and Dirks & Company. From 1993 to 1997, he worked as a research scientist in immunology and gene therapy at New York University, Cornell University and the University of Wisconsin-Madison. Mr. Kahn received his B.S. in Zoology from the University of Wisconsin-Madison.

Back to Top

Kevin P. Olsen joined OrbiMed in 2000 to cover equity trading. Kevin completed a B.S. in Finance and Marketing from the Stern School of Business at New York University.

Back to Top

Jung Ryu is an Analyst supporting the public equities team. Prior to joining OrbiMed, he was an Equity Capital Markets Analyst at JPMorgan covering the healthcare industry. Mr. Ryu completed a B.A. in Economics from Dickinson College.

Back to Top

Haige Lu, Ph.D., is a Public Equity Analyst focused on biotechnology companies. Prior to joining OrbiMed, he worked as a Research Fellow at Memorial Sloan-Kettering Cancer Center. He received his Ph.D. from Stanford University in Chemical Biology and his B.S. in Chemistry from Peking University in China.

Back to Top

Michael R. Metschl is an Analyst supporting the public equity and royalty teams. Prior to joining OrbiMed, he was an investment banking analyst at Citigroup focusing on the life science and medical device sectors. Mr. Metschl received his B.B.A. degree summa cum laude in Finance and Chinese from the University of Notre Dame.

Back to Top